Company news
Mustang Bio, Inc. news in 2025
Mustang Bio, Inc.'s news releases, calls and decks from 2025, newest first.
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
July 7, 2025
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
March 5, 2025
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
February 27, 2025
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 10, 2025
Mustang Bio Announces Closing of $8 Million Public Offering
February 9, 2025
Mustang Bio Announces Pricing of $8 Million Public Offering
February 5, 2025
Mustang Bio Announces Reverse Stock Split
January 13, 2025